Selma Ugurel
Author Correction: Interleukin 17 signaling supports clinical benefit of dual CTLA-4 and PD-1 checkpoint inhibition in melanoma.
Váraljai R, Zimmer L, Al-Matary Y, Kaptein P, Albrecht L, Shannan B, Brase J, Gusenleitner D, Amaral T, Wyss N, Utikal J, Flatz L, Rambow F, Reinhardt H, Dick J, Engel D, Horn S, Ugurel S, Sondermann W, Livingstone E, Sucker A, Paschen A, Zhao F, Placke J, Klose J, Fendler W, Thommen D, Helfrich I, Schadendorf D, Roesch A. Author Correction: Interleukin 17 signaling supports clinical benefit of dual CTLA-4 and PD-1 checkpoint inhibition in melanoma. Nat Cancer 2023; 4:1395.
Sep 1, 2023Author Correction: Interleukin 17 signaling supports clinical benefit of dual CTLA-4 and PD-1 checkpoint inhibition in melanoma.
Sep 1, 2023Nat Cancer 2023; 4:1395
Váraljai Renáta, Zimmer Lisa, Al-Matary Yahya, Kaptein Paulien, Albrecht Lea J, Shannan Batool, Brase Jan C, Gusenleitner Daniel, Amaral Teresa, Wyss Nina, Utikal Jochen, Flatz Lukas, Rambow Florian, Reinhardt Hans Christian, Dick Jenny, Engel Daniel R, Horn Susanne, Ugurel Selma, Sondermann Wiebke, Livingstone Elisabeth, Sucker Antje, Paschen Annette, Zhao Fang, Placke Jan M, Klose Jasmin M, Fendler Wolfgang Peter, Thommen Daniela S, Helfrich Iris, Schadendorf Dirk, Roesch Alexander
Interleukin 17 signaling supports clinical benefit of dual CTLA-4 and PD-1 checkpoint inhibition in melanoma.
Váraljai R, Zimmer L, Al-Matary Y, Kaptein P, Albrecht L, Shannan B, Brase J, Gusenleitner D, Amaral T, Wyss N, Utikal J, Flatz L, Rambow F, Reinhardt H, Dick J, Engel D, Horn S, Ugurel S, Sondermann W, Livingstone E, Sucker A, Paschen A, Zhao F, Placke J, Klose J, Fendler W, Thommen D, Helfrich I, Schadendorf D, Roesch A. Interleukin 17 signaling supports clinical benefit of dual CTLA-4 and PD-1 checkpoint inhibition in melanoma. Nat Cancer 2023; 4:1292-1308.
Jul 31, 2023Interleukin 17 signaling supports clinical benefit of dual CTLA-4 and PD-1 checkpoint inhibition in melanoma.
Jul 31, 2023Nat Cancer 2023; 4:1292-1308
Váraljai Renáta, Zimmer Lisa, Al-Matary Yahya, Kaptein Paulien, Albrecht Lea J, Shannan Batool, Brase Jan C, Gusenleitner Daniel, Amaral Teresa, Wyss Nina, Utikal Jochen, Flatz Lukas, Rambow Florian, Reinhardt Hans Christian, Dick Jenny, Engel Daniel R, Horn Susanne, Ugurel Selma, Sondermann Wiebke, Livingstone Elisabeth, Sucker Antje, Paschen Annette, Zhao Fang, Placke Jan M, Klose Jasmin M, Fendler Wolfgang Peter, Thommen Daniela S, Helfrich Iris, Schadendorf Dirk, Roesch Alexander
Dataset of a retrospective multicenter cohort study on characteristics of immune checkpoint inhibitor-induced encephalitis and comparison with HSV-1 and anti-LGI1 encephalitis.
Müller-Jensen L, Zierold S, Versluis J, Boehmerle W, Huehnchen P, Endres M, Mohr R, Compter A, Blank C, Hagenacker T, Meier F, Reinhardt L, Gesierich A, Salzmann M, Hassel J, Ugurel S, Zimmer L, Banks P, Spain L, Soon J, Enokida T, Tahara M, Kähler K, Seggewiss-Bernhardt R, Harvey C, Long G, Schöberl F, von Baumgarten L, Hundsberger T, Schlaak M, French L, Knauss S, Heinzerling L. Dataset of a retrospective multicenter cohort study on characteristics of immune checkpoint inhibitor-induced encephalitis and comparison with HSV-1 and anti-LGI1 encephalitis. Data Brief 2022; 45:108649.
Sep 30, 2022Dataset of a retrospective multicenter cohort study on characteristics of immune checkpoint inhibitor-induced encephalitis and comparison with HSV-1 and anti-LGI1 encephalitis.
Sep 30, 2022Data Brief 2022; 45:108649
Müller-Jensen Leonie, Zierold Sarah, Versluis Judith M, Boehmerle Wolfgang, Huehnchen Petra, Endres Matthias, Mohr Raphael, Compter Annette, Blank Christian U, Hagenacker Tim, Meier Friedegund, Reinhardt Lydia, Gesierich Anja, Salzmann Martin, Hassel Jessica C, Ugurel Selma, Zimmer Lisa, Banks Patricia, Spain Lavinia, Soon Jennifer A, Enokida Tomohiro, Tahara Makoto, Kähler Katharina C, Seggewiss-Bernhardt Ruth, Harvey Catriona, Long Georgina V, Schöberl Florian, von Baumgarten Louisa, Hundsberger Thomas, Schlaak Max, French Lars E, Knauss Samuel, Heinzerling Lucie M
Characteristics of immune checkpoint inhibitor-induced encephalitis and comparison with HSV-1 and anti-LGI1 encephalitis: A retrospective multicentre cohort study.
Müller-Jensen L, Zierold S, Versluis J, Boehmerle W, Huehnchen P, Endres M, Mohr R, Compter A, Blank C, Hagenacker T, Meier F, Reinhardt L, Gesierich A, Salzmann M, Hassel J, Ugurel S, Zimmer L, Banks P, Spain L, Soon J, Enokida T, Tahara M, Kähler K, Seggewiss-Bernhardt R, Harvey C, Long G, Schöberl F, von Baumgarten L, Hundsberger T, Schlaak M, French L, Knauss S, Heinzerling L. Characteristics of immune checkpoint inhibitor-induced encephalitis and comparison with HSV-1 and anti-LGI1 encephalitis: A retrospective multicentre cohort study. Eur J Cancer 2022; 175:224-235.
Sep 22, 2022Characteristics of immune checkpoint inhibitor-induced encephalitis and comparison with HSV-1 and anti-LGI1 encephalitis: A retrospective multicentre cohort study.
Sep 22, 2022Eur J Cancer 2022; 175:224-235
Müller-Jensen Leonie, Zierold Sarah, Versluis Judith M, Boehmerle Wolfgang, Huehnchen Petra, Endres Matthias, Mohr Raphael, Compter Annette, Blank Christian U, Hagenacker Tim, Meier Friedegund, Reinhardt Lydia, Gesierich Anja, Salzmann Martin, Hassel Jessica C, Ugurel Selma, Zimmer Lisa, Banks Patricia, Spain Lavinia, Soon Jennifer A, Enokida Tomohiro, Tahara Makoto, Kähler Katharina C, Seggewiss-Bernhardt Ruth, Harvey Catriona, Long Georgina V, Schöberl Florian, von Baumgarten Louisa, Hundsberger Thomas, Schlaak Max, French Lars E, Knauss Samuel, Heinzerling Lucie M